An Application to Extend the Use of Rubraca for Treating Ovarian Cancer has Been Submitted to the European Medicines Agency
Clovis Oncology, Inc. has announced that they have submitted an application to the European Medicines Agency (EMA). The application is to extend the drug Rubraca’s®(rucaparib) marketing authorisation to include maintenance…